• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Drug delivery biz fuels healthcare segment growth for 3M

October 24, 2017 By Brad Perriello

3MSales and operating profits for the healthcare business at 3M Cos. (NYSE:MMM) rose during the third quarter, helping the industrial conglomerate top the consensus sales and earnings forecasts and sending share prices up today on Wall Street.

3M Health Care’s operating profits rose 9.3% to $471 million for the three months ended Sept. 30, compared with Q3 2016, on sales growth of 7.7% to $1.48 billion.

Overall profits for the parent company increased 7.5% to $1.43 billion, or $2.33 per share, on sales of growth of 6.0% to $8.17 billion. Analysts on the Street were looking for earnings per share of 2.21 on sales of $7.93 billion.

“Coming off a strong first half, our team delivered an even more robust performance in the third quarter – marked by an 8% increase in earnings per share and 7% organic growth that was positive across all business groups and geographic areas,” chairman, president & CEO Inge Thulin said in prepared remarks. “We also expanded margins to 25 percent, while investing for the future and returning significant cash to our shareholders.”

The news pushed MMM shares up 5.2% to $233.13 apiece today in mid-morning trading and prompted 3M to raise its outlook for the rest of the year.

The St. Paul, Minn.-based company said it now expects to post EPS of $9.00 to $9.10, up from $8.80 to $9.05 previously, on organic, constant-currency sales growth of 4% to 5% (up from prior guidance of 3% to 5%).

Drug delivery fuels health care growth

3M said the healthcare segment growth was powered by top-line growth for its drug delivery business, plus contributions from its food safety, medical consumables and oral care operations. Geographically, the growth was led by the Asia-Pacific region and the Americas, the company said.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: 3M

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS